AstraZeneca announced layoffs of 600 employees on November 13, 2026. AstraZeneca cut about 600 jobs from its US respiratory and immunology commercial teams, including reps who promote the asthma drugs Breztri and Airsupra. The cuts fall under a $1.5 billion annual savings plan the drugmaker set out in late October.